Market Access World USA 2011 - The big idea

Following on from our highly successful European series and its inauguration in 2010, Market Access World USA 2011 will attract a record number of pharma market access thought leaders. This event will provide delegates with the most comprehensive review of US health reform.

The questions you have raised will be addressed directly:

• How will new reimbursement models impact market access? What new data will be required from pharma to support reimbursement under these new models?
   
• How will CER differ from the EU HTA experience? How is it being operationalized and with what impact?
   
• What is the role of real life / observational studies in the future security of market access? How might the requirement for new sources of evidence and real life data be used by payors to inform reimbursement decisions?
   
• HTA agency policy and practice globally: comparing and contrasting different models and their impact on market access. How are HTA agencies sharing evidence globally – how joined up and efficient is the global network?
   
• Seeking early advice and liaison with all stakeholders: when is the optimum time to be considering reimbursability?
   
• Risk sharing, value based pricing, pay for performance: What examples are there of these pricing models being adopted in US, EU and globally?
   
• Quality improvement measures: how will they impact price, perceived value and market access?
   
• How will US health reforms impact state Medicaid programs, including drug coverage? What tools are states using to contain costs?
   
• Speciality and high priced drugs such as oncology: comparing different HTA agency / payer approaches to market access. How are these products and services to be reimbursed?

Market Access World USA 2011 

• Over 100 attendees
• From across the globe
• Senior decision makers